Clostridioides difficile infection (CDI): A pan-European multi-center cost and resource utilization study, results from the Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI)
Sebastian M Wingen-Heimann,Kerrie Davies,Virginie F Viprey,Georgina Davis,Mark H Wilcox,Maria J G T Vehreschild,Lise Lurienne,Pierre-Alain Bandinelli,Oliver A Cornely,Tuba Vilken,Sina M Hopff,Jörg Janne Vehreschild,COMBACTE-CDI consortium,Academic Partners,Marc Bonten,Kerrie A Davies,Ed Kuijper,Maja Rupnik,Sebastian Wingen-Heimann,Evelina Tacconelli,Nicola Petrosillo,Efpia Partners,Pfizer Ltd,GlaxoSmithKline,bioMérieux,Sanofi Pasteur,Da Volterra,The Management Board Of Combacte-Cdi,Philippe Cleuziat,Chris Webber
DOI: https://doi.org/10.1016/j.cmi.2022.12.019
Abstract:Objectives: Clostridioides difficile infection (CDI) is one of the leading nosocomial infections worldwide, resulting in a significantly increasing burden on the healthcare systems. However, Pan-European data about cost and resource utilization of CDI treatment do not exist. Methods: A retrospective analysis within the Combatting Bacterial Resistance in Europe CDI project was conducted based on resource costs for inpatient treatment and productivity costs. Country-specific cost values were converted to EURO referred to 1 January, 2019 values. Differences in price levels for healthcare services among the participating countries were adjusted by using an international approach of the Organisation for Economic Co-operation and Development. As the study focused on patients with recurrent CDI, the observed study population was categorized into (a) patients with CDI but without CDI recurrence (case group), (b) patients with CDI recurrence (recurrence group), and (c) patients without CDI (control group). Results: Overall, 430 hospitalized patients from 12 European countries were included into the analysis between July 2018 and November 2018. Distribution of mean hospital length of stay and mean overall costs per patient between the case group, recurrence group, and control group were as follows: 22 days (95% CI 17-27 days) vs. 55 days (95% CI 17-94 days) vs. 26 days (95% CI 22-31 days; p 0.008) and € 15 242 (95% CI 10 593-19 891) vs. € 52 024 (95% CI 715-103 334) vs. € 21 759 (95% CI 16 484-27 035; p 0.010), respectively. The CDI recurrence rate during the observational period was 18%. Change escalation in CDI medication (OR 3.735) and treatment in an intensive care unit (OR 5.454) were found to be the most important variables associated with increased overall costs of patients with CDI. Conclusions: Treatment of patients with recurrent CDI results in a significant burden. Prevention of CDI recurrences should be in focus of daily patient care to identify the most cost-effective treatment strategy.